A quadruple combination containing quarter doses of four blood pressure (BP)-lowering drugs in a single pill — termed a quadpill — led to better BP control than using monotherapy for initial treatment of hypertension, according to the QUARTET study presented at ESC 2021.
Receiving an influenza vaccination after hospitalization for an invasive coronary procedure or a myocardial infarction (MI) may reduce the risk of all-cause or cardiovascular (CV) death, according to results of the IAMI* trial.
Alcohol consumption during late adolescence and early adulthood was associated with increased arterial stiffness, which may lead to future cardiovascular events, according to a study presented at ESC 2021.
Regular intake of saturated fatty acids (SFA) from meat could increase cardiovascular disease (CVD) risk whereas dairy sources, grains, fruits, and vegetables could be cardio-protective, suggests a study in the UK.
Empagliflozin significantly reduces the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) vs placebo in patients with heart failure with preserved ejection fraction (HFpEF) with or without diabetes, according to results of the EMPEROR-Preserved trial presented at the European Society of Cardiology (ESC) Congress 2021.
After the initial and 3-month doses, twice-yearly dosing of inclisiran led to effective and sustained LDL-C* reduction in patients with and without polyvascular disease (PVD**), according to a pooled analysis of the ORION-9, ORION-10, and ORION-11 phase III trials.
Six months of combined supervised exercise training and home-based physical activity helps to prevent atrial fibrillation (AF) recurrence and severity of symptoms in patients with persistent AF, according to the ACTIVE-AF* study presented at ESC 2021.
Having high serum sodium levels above 142 mmol/L — which is indicative of insufficient fluid intake — is associated with a greater risk of left ventricular hypertrophy (LVH) and heart failure (HF) in later life, according to the ARIC* study presented at ESC 2021 Congress.
In individuals who were discharged following hospitalization due to COVID-19, thromboprophylaxis with the novel oral anticoagulant rivaroxaban for 35 days led to improved clinical outcomes without increased bleeding compared with no anticoagulation post-discharge, according to findings from the MICHELLE* trial.
The Amplatzer™ Amulet™ LAA* Occluder has shown superiority over the Watchman** device in terms of LAA closure and noninferiority in terms of efficacy and safety for preventing stroke in patients with nonvalvular atrial fibrillation (AF), according to findings from the AMULET IDE trial.